Bethesda SystemPapanicolaou System
Benign within normal limitsClass I
Infection: atypical squamous cells of unknown significance (ASCUS)
Reactive and reparative changes: Atypical glandular cells of unknown significance (AGUS)
Class II
Low-grade squamous intraepithelial lesions (LGSIL), human papilloma virus (HPV), mild dysplasiaClass III
Cervical intraepithelial neoplasia (CIN1*)Class III
High grade squamous intraepithelial lesion (HGSIL) including moderate dysplasia, severe dysplasia, carcinoma in situ, and CIN2* Class III
HGSIL including severe dysplasia, carcinoma insitu (CIS**), CIN3*.Class IV
Invasive carcinomaClass V

Source: Shingleton HM, Patrick RL, Johnston WW, Smith RA.: The current status of the Papanicolaou Smear. CA-Cancer Journal for Clinicians. 1995;45(5):309.

*Terminology developed by Richert, RM: Cervical intraepithelial neoplasia. Pathology Annual 1973;8;301-328.

**Terminology developed by Reagan JW, et al: The cellular morphology of carcinoma in situ and dysplasia or atypical hyperplasia of the uterine cervix. Cancer 1953;6:224-235.

From: New Technologies for Cervical Cancer Screening

Cover of Minnesota Health Technology Assessments
Minnesota Health Technology Assessments [Internet].
Minnesota Health Technology Advisory Committee.
St. Paul (MN): Minnesota Department of Health; 1995-2001.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.